Search Results

1 - 9 of 9 items :

Clear All
Polyphenols treatment in patients with nonalcoholic fatty liver disease

Introduction In the last few decades, the term nonalcoholic fatty liver disease (NAFLD) has been evoked increasingly in research frameworks and in clinical practice. It defines the presence of significant fat accumulation in the liver (> 5% of hepatocytes), in the absence of alcohol abuse and any other cause of liver diseases.[ 1 ] The term NAFLD includes different clinical entities, and in particular, the fat accumulation in liver, also known as simple fatty liver and nonalcoholic steatohepatitis (NASH); it is characterized by steatosis along with

Open access
Effect of weight reduction on histological activity and fibrosis of lean nonalcoholic steatohepatitis patient

Introduction Non-alcoholic fatty liver disease (NAFLD), the most prevalent chronic liver disorder worldwide, is a clinico-histopathological entity ranging from simple fat accumulation (steatosis) to non-alcoholic steatohepatitis (NASH). [ 1 , 2 ] NASH is diagnosed by the joint presence of steatosis and inflammation along with hepatocyte injury (evident as hepatocyte ballooning). [ 3 ] It is estimated that NASH occurs in 20% of patients with NAFLD, whereas in Bangladesh, it shows a higher proportion (42.4%). [ 4 , 5 ] Due to its progressive nature

Open access
Effect of pentoxifylline on histological activity and fibrosis of nonalcoholic steatohepatitis patients: A one year randomized control trial

Introduction Non-alcoholic fatty liver disease (NAFLD) is a condition pathologically linked to the metabolic syndrome by the intervention of insulin resistance (IR), characterized by hepatic steatosis in the absence of significant alcohol use, hepatotoxic medications or other known liver diseases.[ 1 ] Globally, the prevalence of NAFLD is 25.24%.[ 2 ] In the Asia-Pacific region, the prevalence of NAFLD has increased remarkably over the years affecting up to 30% of the general population.[ 3 ] In case of NAFLD, Bangladeshi ethnicity is an independent risk

Open access
Unusual presentation of nonalcoholic steatohepatitis-related cirrhosis in a patient with celiac disease and microscopic colitis


Nonalcoholic steatohepatitis (NASH) is defined as the presence of hepatic steatosis and inflammation with hepatocyte injury (ballooning) with or without fibrosis. NASH is often a “silent” liver disease. Estimated prevalence of NASH ranges from 3% to 5% in different studies. The prevalence of NASH-related cirrhosis in the general population is not known. Herein, we report a case of a young female presented with NASH-related cirrhosis in the setting of poorly controlled celiac disease (CD) and microscopic colitis. A variety of liver abnormalities have been observed in patients with CD, but this unique constellation of the gut and liver pathologies has not been reported previously.

Open access
Resistin levels in non-alcoholic fatty liver disease pathogenesis

insulin resistance and obesity.[ 2 ] Resistin is also expressed in liver cells, where its production seems to increase with the progression of liver damage. In histologically confirmed NAFLD studies, the higher circulating levels of resistin were reported in patients with simple fat accumulation, or non-alcoholic steatohepatitis than in controls.[ 3 ] However, literature also reported similar resistin levels in patients with simple steatosis compared to steatohepatitis.[ 4 ] On this topic, we have previously published a study on the relationship between the serum

Open access
Lipodystrophy HIV-related and FGF21: A new marker to follow the progression of lipodystrophy?

. Hormone-like fibroblast growth factors and metabolic regulation Biochim Biophys Acta 2011 1812 791 5 4 Kharitonenkov A, Larsen P. FGF21 reloaded: challenges of a rapidly growing field. Trends Endocrinol Metab 2011;22:81-6. 10.1016/j.tem.2010.11.003 Kharitonenkov A Larsen P. FGF21 reloaded: challenges of a rapidly growing field Trends Endocrinol Metab 2011 22 81 6 5 Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, et al , Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet

Open access
Obesity diabetes and the role of bile acids in metabolism

[ 12 ] . This is in keeping with the results of bile diversion to the distal small intestine, which also results in improved weight loss, glucose tolerance, and hepatic steatosis through a 10-fold increase in bile acids. The FGF15 expression was decreased [ 35 ] . Gastric bypass operations reduced FOXO1 in the liver in diabetic rats but also in the pancreatic B cell, raising the possibility that this regulator in the pancreas may also be in part a cause of the improvement in glucose tolerance [ 65 , 66 ] . Conclusion In conclusion, the knowledge of the role

Open access
Hepatic encephalopathy in patients in Lviv (Ukraine)

steatosis to cirrhosis. Hepatology 2006; 43: S99–112. Farrell GC Larter CZ Nonalcoholic fatty liver disease: from steatosis to cirrhosis Hepatology 2006 43 S99–112 56 Panagaria N, Varma K, Nijhawan S, Mathur A, Rai RR. Quality of life and nutritional status in alcohol addicts and patients with chronic liver disease. Trop. Gastroenterol 2007; 28: 171–5. Panagaria N Varma K Nijhawan S Mathur A Rai RR Quality of life and nutritional status in alcohol addicts and patients with chronic liver disease Trop. Gastroenterol 2007 28 171 – 5 57

Open access
Importance of studying the levels of hepcidin and vitamin D in Egyptian children with chronic hepatitis C

stores upregulate hepcidin expression, while anemia, hypoxia, and oxidative stress downregulate it. [ 4 , 5 ] Hepcidin is recognized as a biomarker for systemic inflammatory states because of upregulation by inflammatory cytokines. [ 3 , 4 , 5 , 6 ] Patients with chronic liver disease (CLD) usually have iron overload, especially hepatitis C virus (HCV), steatosis, and cirrhotic liver; this iron produces free oxygen radicals with harmful effects on various organs. This consensus pay attention to studying the overall iron homeostasis and the regulatory mechanisms

Open access